BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 4, 2012--
Laboratory Corporation of America® Holdings (LabCorp®)
(NYSE: LH) today announced that David P. King, Chairman and Chief
Executive Officer, is scheduled to speak at the 30th Annual
J.P. Morgan Healthcare Conference in San Francisco, CA. LabCorp’s
presentation is planned for Tuesday, January 10, 2012 at 3:30 p.m. (PST).
A live audio webcast of the presentation will be available via the
Company Web site at www.labcorp.com
and archived for replay.
About LabCorp®
Laboratory Corporation of America® Holdings, an S&P 500
company, is a pioneer in commercializing new diagnostic technologies and
the first in its industry to embrace genomic testing. With annual
revenues of $5.0 billion in 2010, over 31,000 employees worldwide, and
more than 220,000 clients, LabCorp offers a broad test menu ranging from
routine blood analyses to reproductive genetics to DNA sequencing.
LabCorp furthers its scientific expertise and innovative clinical
testing technology with its Centers of Excellence: The Center for
Molecular Biology and Pathology, National Genetics Institute, ViroMed
Laboratories, Inc., The Center for Esoteric Testing, Litholink
Corporation, Genzyme GeneticsSM*, DIANON Systems,
Inc., US LABS, Monogram Biosciences, Inc., and Esoterix and its Colorado
Coagulation, Endocrine Sciences, and Cytometry Associates laboratories.
LabCorp conducts clinical trials testing through its Esoterix Clinical
Trials Services division. LabCorp clients include physicians, government
agencies, managed care organizations, hospitals, clinical labs, and
pharmaceutical companies. To learn more about our organization, visit
our Web site at: www.labcorp.com.
*Genzyme Genetics and its logo are trademarks of Genzyme Corporation
and used by Esoterix Genetic Laboratories, LLC, a wholly-owned
subsidiary of LabCorp, under license. Esoterix Genetic Laboratories and
LabCorp are operated independently from Genzyme Corporation.
This press release contains forward-looking statements. Each of the
forward-looking statements is subject to change based on various
important factors, including without limitation, competitive actions in
the marketplace and adverse actions of governmental and other
third-party payors. Actual results could differ materially from
those suggested by these forward-looking statements. Further information
on potential factors that could affect LabCorp’s financial results is
included in the Company’s Form 10-K for the year ended December 31,
2010, and subsequent SEC filings.
Source: Laboratory Corporation of America(R) Holdings
Investor/Media Contact
Laboratory Corporation of America®
Holdings
Stephen Anderson, 336-436-5274
www.labcorp.com
